Savara price target lowered to $9 from $10 at JMP Securities

JMP Securities analyst Jonathan Wolleben lowered the firm’s price target on Savara to $9 from $10 and keeps an Outperform rating on the shares. Savara remains on track to submit its NDA for Molbreevi in the first half of 2025, to potentially be the first- approved therapeutic for Autoimmune Pulmonary Alveolar Proteinosis, or aPAP, the analyst tells investors in a research note. The firm was impressed with the IMPALA-2 data that showed a clear diffusing capacity of the lungs for carbon monoxide benefit for Molbreevi, with improvement in key functional endpoints that should support approval, which the firm thinks is highly likely.